Xcout Intel
ARTBIO
ARTBIO is a biotechnology company developing targeted alpha-particle radioligand therapies for cancer, including treatments intended to selectively deliver radioactive payloads to tumor cells. Its work is aimed at serving oncology patients and healthcare providers treating solid tumors.
Subscribe to see ARTBIO’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ARTBIO at a glance
ARTBIO is a biotech company headquartered in Norway. Xcout tracks 31 named people at ARTBIO, including Jonathan Freeman, Ph.D (Interim CEO). Xcout recorded 6 job postings from ARTBIO in the last 90 days.
ARTBIO leadership
- Jonathan Freeman, Ph.DInterim CEO
- Philippe Dasse, PharmDChief Technical Officer
- Amra DemirovicChief Human Resources Officer
- Jordi Vall-llosera Ferran, MScChief Quality Officer
- Margaret Yu, MDChief Medical Officer
- Nicole HadasChief Legal Officer
25 more named people on record for ARTBIO, with roles, board committees and tenure — see the full roster →
Hiring at ARTBIO
Xcout recorded 6 job postings from ARTBIO in the last 90 days, from a hiring record Xcout has kept since September 2026.
The weekly hiring trend, the roles and locations behind it — see ARTBIO's hiring signals →
ARTBIO competitors
A few of ARTBIO's closest competitors — see the full list of competitors and alternatives →
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that develops targeted, bespoke molecules using peptide engineering and iterative design to treat cancer patients with precision. The company advances a portfolio of radiotherapeutics utilizing optimized binders, linkers, chelators, and radioisotopes for solid tumors.
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
ITM Isotope Technologies Munich SE develops and supplies targeted radiopharmaceuticals, including diagnostics and therapeutics, for cancer care. The company focuses on precision oncology treatments such as radioligand therapies for hard-to-treat tumors and produces medical radioisotopes like Lutetium-177 and Actinium-225 to serve patients globally.
Laigo Bio is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary SureTAC platform. The company utilizes bispecific antibodies to direct cell surface targets toward lysosomal degradation, primarily serving the oncology and immunology sectors.
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Northern Biologics is a biotechnology company developing antibody-based therapeutics, with a focus on treating cancer and targeting the tumor microenvironment. Its products are intended for oncology patients and clinical partners in the biopharmaceutical sector.
Get ARTBIO's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ARTBIO in Xcout Intel
- 31 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access